<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kurskvest</journal-id><journal-title-group><journal-title xml:lang="ru">Человек и его здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Humans and their health</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-5746</issn><issn pub-type="epub">1998-5754</issn><publisher><publisher-name>Kursk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="edn" pub-id-type="custom">ZBENXG</article-id><article-id custom-type="elpub" pub-id-type="custom">kurskvest-1496</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MEDICOBIOLOGICAL SCIENCES</subject></subj-group></article-categories><title-group><article-title>Иммуномодулирующее действие интервальной гипокситерапии и стимулированной гиперкапнии при гипертонической болезни: влияние на уровни Hsp70, NF-κB и цитокиновый профиль</article-title><trans-title-group xml:lang="en"><trans-title>Immunomodulatory effects of interval hypoxic therapy and stimulated hypercapnia in hypertensive disease: impact on Hsp70, NF-κB levels, and cytokine profile</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1180-228X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борукаева</surname><given-names>Ирина Хасанбиевна</given-names></name><name name-style="western" xml:lang="en"><surname>Borukaeva</surname><given-names>Irina Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, доцент, зав. кафедрой нормальной и патологической физиологии человека медицинской академии, КБГУ, г. Нальчик</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Head of the Department of Normal and Pathological Human Physiology, KBSU, Nalchik, Russian Federation</p></bio><email xlink:type="simple">irborukaeva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-9780-6206</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ашагре</surname><given-names>Сарон Мерша</given-names></name><name name-style="western" xml:lang="en"><surname>Ashagre</surname><given-names>Saron M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирантка кафедры нормальной и патологической физиологии человека медицинской, КБГУ, г. Нальчик</p></bio><bio xml:lang="en"><p>Post-graduate student of the Department of Normal and Pathological Human Physiology, KBSU, Nalchik, Russian Federation</p></bio><email xlink:type="simple">srm19850103@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2827-5068</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абазова</surname><given-names>Залина Хасановна</given-names></name><name name-style="western" xml:lang="en"><surname>Abazova</surname><given-names>Zalina Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доцент, доцент кафедры нормальной и патологической физиологии человека медицинской академии, КБГУ, г. Нальчик</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor at the Department of Normal and Pathological Human Physiology, KBSU, Nalchik, Russian Federation</p></bio><email xlink:type="simple">zalina.abazova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7152-3576</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Умов</surname><given-names>Тембулат Алимбекович</given-names></name><name name-style="western" xml:lang="en"><surname>Umov</surname><given-names>Tembulat A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>cтудент, КБГУ, г. Нальчик</p></bio><bio xml:lang="en"><p>Student, KBSU, Nalchik, Russian Federation</p></bio><email xlink:type="simple">tembulat.umov@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-6413-2904</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шаваева</surname><given-names>Алина Тимуровна</given-names></name><name name-style="western" xml:lang="en"><surname>Shavaeva</surname><given-names>Alina T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>cтудент, КБГУ, г. Нальчик</p></bio><bio xml:lang="en"><p>Student, KBSU, Nalchik, Russian Federation</p></bio><email xlink:type="simple">savaevaalina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Кабардино-Балкарский государственный университет им. Х.М. Бербекова (КБГУ)<country>Россия</country></aff><aff xml:lang="en">Kabardino-Balkarian State University named after Kh.M. Berbekov (KBSU)<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>02</month><year>2026</year></pub-date><volume>28</volume><issue>4</issue><fpage>123</fpage><lpage>130</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Борукаева И.Х., Ашагре С.М., Абазова З.Х., Умов Т.А., Шаваева А.Т., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Борукаева И.Х., Ашагре С.М., Абазова З.Х., Умов Т.А., Шаваева А.Т.</copyright-holder><copyright-holder xml:lang="en">Borukaeva I.K., Ashagre S.M., Abazova Z.K., Umov T.A., Shavaeva A.T.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.kursk-vestnik.ru/jour/article/view/1496">https://www.kursk-vestnik.ru/jour/article/view/1496</self-uri><abstract><p>В патогенезе гипертонической болезни ключевую роль играют стресс-индуцированные шапероны семейства Hsp70 и транскрипционный фактор NF-κB, регулирующий воспалительные и иммунные ответы.</p><p>Цель - оценить воздействие нормобарической интервальной гипокситерапии в сочетании со стимулированной гиперкапнией на иммунологические параметры у пациентов с гипертонической болезнью I стадии.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 160 мужчин с гипертонической болезнью I стадии в возрасте 35-50 лет. Концентрация Hsp70, интерлейкинов IL-6, IL-10 и TNF-α в сыворотке крови и транскрипционного фактора NF-κB в мононуклеарах крови определялась методом твердофазного иммуноферментного анализа до и после проведения курса гипокситерапии.</p></sec><sec><title>Результаты</title><p>Результаты. После 18-дневного курса у пациентов наблюдалось достоверное снижение уровней Hsp70 с 3,65 ± 0,24 до 2,95 ± 0,23 нг/мл (p&lt;0,05) и NF-κB - с 5,67 ± 0,31 до 4,45 ± 0,36 нг/мл (p&lt;0,05), а также нормализация цитокинового профиля крови: снижение уровней IL-6 и TNF-α соответственно с 7,21 ± 0,31 до 6,34 ± 0,22 пг/мл (p&lt;0,05) и с 4,63 ± 0,34 до 3,56 ± 0,27 пг/мл (p&lt;0,05), и увеличение L-10 с 2,41 ± 0,18 до 3,18 ± 0,26 пг/мл (p&lt;0,05). Между IL-6, TNF-α и уровнем артериального давления выявлены значимые положительные корреляции. Отмечено ослабление оксидативного стресса: уменьшение малонового диальдегида и рост активности антиоксидантных ферментов.</p></sec><sec><title>Заключение</title><p>Заключение. Комбинация интервальной гипокситерапии и стимулированной гиперкапнии у больных гипертонической болезнью I стадии снижает Hsp70 и NF-κB, нормализует цитокиновый профиль и уменьшает оксидативный стресс, что подтверждает ее иммуномодулирующий и противовоспалительный эффект.</p></sec></abstract><trans-abstract xml:lang="en"><p>In the pathogenesis of hypertension, stress-induced Hsp70 family chaperones and the transcription factor NF-κB, which regulates inflammatory and immune responses, play key roles.</p><p>Objective - to assess the effects of normobaric intermittent hypoxic therapy combined with stimulated hypercapnia on immunological parameters in patients with stage I hypertension.</p><sec><title>Materials and methods</title><p>Materials and methods. 160 men aged 35-50 years with stage I hypertension were examined. Serum concentrations of Hsp70, interleukins IL-6, IL-10, TNF-α, and NF-κB levels in blood mononuclear cells were measured by solid-phase ELISA before and after the hypoxic therapy course.</p></sec><sec><title>Results</title><p>Results. After an 18-day course, patients showed significant decreases in Hsp70 from 3.65±0.24 to 2.95±0.23 ng/mL (p&lt;0.05) and NF-κB from 5.67±0.31 to 4.45±0.36 ng/mL (p&lt;0.05), along with normalization of the cytokine profile: IL-6 and TNF-α decreased from 7.21±0.31 to 6.34±0.22 pg/mL (p&lt;0.05) and from 4.63±0.34 to 3.56±0.27 pg/mL (p&lt;0.05), respectively, while IL-10 increased from 2.41±0.18 to 3.18±0.26 pg/mL (p&lt;0.05). Significant positive correlations were found between IL-6, TNF-α, and blood pressure levels. Oxidative stress was attenuated, with a decrease in malondialdehyde and increased activity of antioxidant enzymes.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with stage I hypertension, the combination of intermittent hypoxic therapy and stimulated hypercapnia reduces Hsp70 and NF-κB, normalizes the cytokine profile, and lowers oxidative stress, confirming its immunomodulatory and anti-inflammatory effects.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гипертоническая болезнь</kwd><kwd>Hsp70</kwd><kwd>NF-κB</kwd><kwd>цитокины</kwd><kwd>гипокситерапия</kwd><kwd>гиперкапния</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>Hsp70</kwd><kwd>NF-κB</kwd><kwd>cytokines</kwd><kwd>intermittent hypoxia</kwd><kwd>hypercapnia</kwd><kwd>inflammation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И., Барбараш О.Л., Бобкова Н.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117.DOI:10.15829/1560-4071-2024-6117. EDN: GUEWLU.</mixed-citation><mixed-citation xml:lang="en">Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Bobkova N.V., et al. 2024 Clinical practice guidelines for Hypertension in adults.Russian Journal of Cardiology. 2024;29(9):6117 (in Russ.). DOI:10.15829/1560-4071-2024-6117. EDN: GUEWLU.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi G.P., Bagordo D., Rossi F.B., Pintus G., Rossitto G., Seccia T.M. 'Essential' arterial hypertension: time for a paradigm change. J Hypertens. 2024;42(8):1298-1304. DOI: 10.1097/HJH.0000000000003767.</mixed-citation><mixed-citation xml:lang="en">Rossi G.P., Bagordo D., Rossi F.B., Pintus G., Rossitto G., Seccia T.M. 'Essential' arterial hypertension: time for a paradigm change. J Hypertens. 2024;42(8):1298-1304. DOI: 10.1097/HJH.0000000000003767.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Weinstein S, Leibowitz A. Role of the immune system in the pathogenesis of hypertension. Harefuah. 2021;160(4):256-259.</mixed-citation><mixed-citation xml:lang="en">Weinstein S, Leibowitz A. Role of the immune system in the pathogenesis of hypertension. Harefuah. 2021;160(4):256-259.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lazaridis A., Gavriilaki E., Douma S., Gkaliagkousi E. Toll-Like Receptors in the Pathogenesis of Essential Hypertension. A Forthcoming Immune-Driven Theory in Full Effect.Int J Mol Sci. 2021;22(7):3451. DOI: 10.3390/ijms22073451.</mixed-citation><mixed-citation xml:lang="en">Lazaridis A., Gavriilaki E., Douma S., Gkaliagkousi E. Toll-Like Receptors in the Pathogenesis of Essential Hypertension. A Forthcoming Immune-Driven Theory in Full Effect.Int J Mol Sci. 2021;22(7):3451. DOI: 10.3390/ijms22073451.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jia X.Y., Jiang D.L., Jia X.T., Fu L.Y., Tian H., Liu K.L., Qi J., Kang Y.M., et al. Capsaicin improves hypertension and cardiac hypertrophy via SIRT1/NF-κB/MAPKs pathway in the hypothalamic paraventricular nucleus. Phytomedicine. 2023;118:154951. DOI: 10.1016/j.phymed.2023.154951.</mixed-citation><mixed-citation xml:lang="en">Jia X.Y., Jiang D.L., Jia X.T., Fu L.Y., Tian H., Liu K.L., Qi J., Kang Y.M., et al. Capsaicin improves hypertension and cardiac hypertrophy via SIRT1/NF-κB/MAPKs pathway in the hypothalamic paraventricular nucleus. Phytomedicine. 2023;118:154951. DOI: 10.1016/j.phymed.2023.154951.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gaptulbarova K.A., Tsyganov M.M., Pevzner A.M., Ibragimova M.K., Litviakov N.V. NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Exp Oncol. 2020;42(4):263-269. DOI: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15414.</mixed-citation><mixed-citation xml:lang="en">Gaptulbarova K.A., Tsyganov M.M., Pevzner A.M., Ibragimova M.K., Litviakov N.V. NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Exp Oncol. 2020;42(4):263-269. DOI: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15414.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yu M., Wu X., Wang J., He M., Han H., Hu S., Xu J., Yang M., et al. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.Int J Med Sci. 2022;19(4):681-694. DOI: 10.7150/ijms.69289.</mixed-citation><mixed-citation xml:lang="en">Yu M., Wu X., Wang J., He M., Han H., Hu S., Xu J., Yang M., et al. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.Int J Med Sci. 2022;19(4):681-694. DOI: 10.7150/ijms.69289.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Борукаева И.Х., Абазова З.Х., Шхагумов К.Ю., Темиржанова Ф.Х., Ашагре С.М., Рагимбайова М.Р. Патофизиологические механизмы эффективности интервальной гипокситерапии и энтеральной оксигенотерапии в лечении больных гипертонической болезнью. Российский кардиологический журнал. 2021;26(S6):17.EDN: YMQSMH.</mixed-citation><mixed-citation xml:lang="en">Borukaeva I.Kh., Abazova Z.Kh., Shkhagumov K.Yu., Temirzhanova F.Kh., Ashagre S.M., Ragimbayeva M.R. Pathophysiological mechanisms underlying the effectiveness of interval hypoxic therapy and enteral oxygen therapy in the treatment of patients with hypertension.Russian Journal of Cardiology, 2021;26(S6):17 (in Russ.). EDN: YMQSMH.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатенко Г.А., Багрий А.Э., Игнатенко Т.С., Толстой В.А., Евтушенко И.С., Михайличенко Е.С. Возможности и перспективы применения гипокситерапии в кардиологии. Архивъ внутренней медицины. 2023;13(4):245-252.DOI: 10.20514/2226-6704-2023-13-4-245-252. EDN: AHXHPL.</mixed-citation><mixed-citation xml:lang="en">Ignatenko G.A., Bagriy A.E., Ignatenko T.S., Tolstoy V.A., Evtushenko I.S., Mykhailichenko E.S. Possibilities and Prospects of Hypoxytherapy Application in Cardiology. The Russian Archives of Internal Medicine. 2023;13(4):245-252 (in Russ.). DOI: 10.20514/2226-6704-2023-13-4-245-252. EDN: AHXHPL.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Велижанина И.А., Гапон Л.И., Евдокимова О.В., Велижанина Е.С., Рудаков А.В. Оценка эффективности прерывистой нормобарической гипокситерапии в лечении артериальной гипертонии по данным суточного мониторирования артериального давления. Клиническая практика. 2017;(4):51-55.EDN: YWSVWL</mixed-citation><mixed-citation xml:lang="en">Velizhanina I.A., Gapon L.I., Evdokimova O.V., Velizhanina E.S., Rudakov A.V. Evaluation of the effectiveness of intermittent normobaric hypoxic therapy in the treatment of arterial hypertension based on 24-hour ambulatory blood pressure monitoring. Clinical Practice. 2017;(4):51-55. (in Russ.). EDN: YWSVWL</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Борукаева И.Х., Абазова З.Х., Иванов А.Б., Мисирова И.А., Шхагумов К.Ю., Шаваева Ф.В., Молов А.А., Кипкеева Т.Б., Шокуева А.Г. Сохранение иммуномодулирующего действия интервальной гипокситерапии после коронавирусной инфекции в отдаленном периоде. Медицинская иммунология. 2023;25(4):809-814.DOI: 10.15789/1563-0625-POT-2767. EDN: YFNCZG.</mixed-citation><mixed-citation xml:lang="en">Borukaeva I.Kh., Abazova Z.Kh., Ivanov A.B., Misirova I.A., Shkhagumov K.Yu., Shavaeva F.V., Mоlov A.A., Kipkeeva T.B., Shokueva A.G. Preservation of the immunomodulatory effect of interval hypoxytherapy after coronavirus infection in the long-term period. Medical Immunology. 2023;25(4):809-814 (in Russ.). DOI: 10.15789/1563-0625-POT-2767. EDN: YFNCZG.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Шишкина О.С. Дыхательная гимнастика К.П. Бутейко и ее влияние на организм человека. Международный научный журнал «ВЕСТНИК НАУКИ». 2022;11(56):161-163.</mixed-citation><mixed-citation xml:lang="en">Shishkina O.S. Buteiko breathing exercises &amp; Its effect on human body.International scientific journal "BULLETIN OF SCIENCE". 2022;11(56):161-163 (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Салимова С.С., Беркинбай А.Б., Кожахан С.С., Абдикаим Д.Г., Абдилахат У.Т., Джазыкпаева Э.Т., Серикжан Ф.С., Ергешбай Б.К., и др. Эффективность тренировок дыхания по методу Бутейко у пациентов с хронической обструктивной болезнью легких. Фтизиопульмонология. 2025;1(47):151-161.DOI: 10.26212/2227-1937.2025.56.29.018. EDN: GDHGSV.</mixed-citation><mixed-citation xml:lang="en">Salimova S.S., Berkinbay A.B., Kozhakhan S.S., Abdikaim D.G., Abdilakhat U.T., Dzhazykpayeva E.T., Serikzhan F.S., Yergeshbay B.K., et al. The effectiveness of Buteyko breathing training in patients with chronic obstructive pulmonary disease. Phthisiopulmonology. 2025;1(47):151-161 (in Russ.). DOI: 10.26212/2227-1937.2025.56.29.018. EDN: GDHGSV.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Косарев М.О., Садова В.А., Сумная Д.Б., Николаева И.В. Гиперкапнически-гипоксические тренировки с помощью дыхательного тренажера «Карбоник» у пациентов с хронической ишемией головного мозга атеросклеротического генеза. German International Journal of Modern Science. 2021;9:21-25.DOI: 10.24412/2701-8369-2021-9-1-21-25. EDN: ZBZZJK.</mixed-citation><mixed-citation xml:lang="en">Kosarev M.O., Sadova V.A., Sumnaya D.B., Nikolaeva I.V. Hypercapnic-hypoxic training with the aid respiratory simulator "CARBONIC" in patients with chronic ischemia of the brain of atherosclerotic genesis. German International Journal of Modern Science. 2021;9:21-25 (in Russ.). DOI: 10.24412/2701-8369-2021-9-1-21-25. EDN: ZBZZJK.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Трегуб П.П. Влияние гиперкапнии и гипоксии на физиологию и метаболизм церебрального эндотелия в условиях ишемии. Российский физиологический журнал им. И.М. Сеченова. 2022;108(5): 579-593. DOI: 10.31857/S0869813922050120. EDN: TDITXD.</mixed-citation><mixed-citation xml:lang="en">Tregub P.P. The Effect of Hypercapnia and Hypoxia on the Physiology and Metabolism of the Cerebral Endothelium in Ischemic Conditions. I.M. Sechenov Russian Journal of Physiology. 2022;108(5):579-593. DOI: 10.31857/S0869813922050120. EDN: TDITXD.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y., Wang K., Di J., Guan C., Wang S., Li Q., Qu Y. Mutation of the BAG-1 domain decreases its protective effect against hypoxia/reoxygenation by regulating HSP70 and the PI3K/AKT signalling pathway in SY-SH5Y cells. Brain Res. 2021;1751:147192. DOI: 10.1016/j.brainres.2020.147192.</mixed-citation><mixed-citation xml:lang="en">Chen Y., Wang K., Di J., Guan C., Wang S., Li Q., Qu Y. Mutation of the BAG-1 domain decreases its protective effect against hypoxia/reoxygenation by regulating HSP70 and the PI3K/AKT signalling pathway in SY-SH5Y cells. Brain Res. 2021;1751:147192. DOI: 10.1016/j.brainres.2020.147192.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Madaeva I.M., Kurashova N.A., Semenova N.V., Ukhinov E.B., Kolesnikov S.I., Kolesnikova L.I. Heat Shock Protein HSP70 in Oxidative Stress in Apnea Patients. Bull Exp Biol Med. 2020;169(5):695-697. DOI: 10.1007/s10517-020-04957-9.</mixed-citation><mixed-citation xml:lang="en">Madaeva I.M., Kurashova N.A., Semenova N.V., Ukhinov E.B., Kolesnikov S.I., Kolesnikova L.I. Heat Shock Protein HSP70 in Oxidative Stress in Apnea Patients. Bull Exp Biol Med. 2020;169(5):695-697. DOI: 10.1007/s10517-020-04957-9.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shobatake R., Ota H., Takahashi N., Ueno S., Sugie K., Takasawa S. The Impact of Intermittent Hypoxia on Metabolism and Cognition.Int. J. Mol. Sci. 2022;23,12957. DOI: 10.3390/ijms232112957.</mixed-citation><mixed-citation xml:lang="en">Shobatake R., Ota H., Takahashi N., Ueno S., Sugie K., Takasawa S. The Impact of Intermittent Hypoxia on Metabolism and Cognition.Int. J. Mol. Sci. 2022;23,12957. DOI: 10.3390/ijms232112957.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J.R., Liu Q., Khoury J., Li Y.J., Han X.H., Li J., Ibla J.C. Hypoxic preconditioning decreases nuclear factor κB activity via Disrupted in Schizophrenia-1.Int J Biochem Cell Biol. 2016;70:140-148. DOI: 10.1016/j.biocel.2015.11.013.</mixed-citation><mixed-citation xml:lang="en">Liu J.R., Liu Q., Khoury J., Li Y.J., Han X.H., Li J., Ibla J.C. Hypoxic preconditioning decreases nuclear factor κB activity via Disrupted in Schizophrenia-1.Int J Biochem Cell Biol. 2016;70:140-148. DOI: 10.1016/j.biocel.2015.11.013.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Korbecki J., Simińska D., Gąssowska-Dobrowolska M., Listos J., Gutowska I., Chlubek D., Baranowska-Bosiacka I. Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms.Int J Mol Sci. 2021;22(19):10701. DOI: 10.3390/ijms221910701.</mixed-citation><mixed-citation xml:lang="en">Korbecki J., Simińska D., Gąssowska-Dobrowolska M., Listos J., Gutowska I., Chlubek D., Baranowska-Bosiacka I. Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms.Int J Mol Sci. 2021;22(19):10701. DOI: 10.3390/ijms221910701.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Y., Li Y., Ran X., Wang D., Zheng X., Zhang M., Yu B., Sun Y., et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. Cell Mol Life Sci. 2022;79(6):311. DOI: 10.1007/s00018-022-04331-0.</mixed-citation><mixed-citation xml:lang="en">Zheng Y., Li Y., Ran X., Wang D., Zheng X., Zhang M., Yu B., Sun Y., et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. Cell Mol Life Sci. 2022;79(6):311. DOI: 10.1007/s00018-022-04331-0.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schumertl T., Lokau J., Garbers C. IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention. Immunotargets Ther. 2025;14:681-695. DOI: 10.2147/ITT.S485684.</mixed-citation><mixed-citation xml:lang="en">Schumertl T., Lokau J., Garbers C. IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention. Immunotargets Ther. 2025;14:681-695. DOI: 10.2147/ITT.S485684.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou L., Zhang H., Liu L., Zhang F., Wang L., Zheng P., Mao Z., Zhu X., et al.Intermittent hypoxia aggravates asthma inflammation via NLRP3/IL-1β-dependent pyroptosis mediated by HIF-1α signalling pathway. Chin Med J (Engl). 2025;138(14):1714-1729. DOI: 10.1097/CM9.0000000000003608.</mixed-citation><mixed-citation xml:lang="en">Zhou L., Zhang H., Liu L., Zhang F., Wang L., Zheng P., Mao Z., Zhu X., et al.Intermittent hypoxia aggravates asthma inflammation via NLRP3/IL-1β-dependent pyroptosis mediated by HIF-1α signalling pathway. Chin Med J (Engl). 2025;138(14):1714-1729. DOI: 10.1097/CM9.0000000000003608.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mishra B., Mishra B., Bachu M., Yuan R., Wingert C., Chaudhary V., Brauner C., Bell R., et al. IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms. Nat Immunol. 2025 May;26(5):748-759. DOI: 10.1038/s41590-025-02137-3.</mixed-citation><mixed-citation xml:lang="en">Mishra B., Mishra B., Bachu M., Yuan R., Wingert C., Chaudhary V., Brauner C., Bell R., et al. IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms. Nat Immunol. 2025 May;26(5):748-759. DOI: 10.1038/s41590-025-02137-3.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sato T., Takeda N. The roles of HIF-1α signaling in cardiovascular diseases. J Cardiol. 2023;81(2):202-208. DOI: 10.1016/j.jjcc.2022.09.002.</mixed-citation><mixed-citation xml:lang="en">Sato T., Takeda N. The roles of HIF-1α signaling in cardiovascular diseases. J Cardiol. 2023;81(2):202-208. DOI: 10.1016/j.jjcc.2022.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Титова О.Н., Кузубова Н.А., Лебедева Е.С. Роль гипоксийного сигнального пути в адаптации клеток к гипоксии. РМЖ. Медицинское обозрение. 2020;4(4):207-213. DOI: 10.32364/2587-6821-2020-4-4-207-213. EDN: EQPBIM.</mixed-citation><mixed-citation xml:lang="en">Titova O.N., Kuzubova N.A., Lebedeva E.S. The role of the hypoxia signaling pathway in cellular adaptation to hypoxia.Russian Medical Inquiry. 2020;4(4):207-213 (in Russ.). DOI: 10.32364/2587-6821-2020-4-4-207-213. EDN: EQPBIM.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Балыкин М.В., Сагидова С.А., Жарков А.С., Айзятулова Е.Д., Павлов Д.А., Антипов И.В. Влияние прерывистой гипобарической гипоксии на экспрессию HIF-1Α и морфофункциональные изменения в миокарде. Ульяновский медико-биологический журнал. 2017;2:125-135. DOI: 10.23648/UMBJ.2017.26.6227. EDN: YTFJCP.</mixed-citation><mixed-citation xml:lang="en">Baly`kin M.V., Sagidova S.A., Zharkov A.S., Ajzyatulova E.D., Pavlov D.A., Antipov I.V. The effect of intermittent hypobaric hypoxia on HIF-1Α expression and morphofunctional changes in the myocardium. Ul`yanovskij mediko-biologicheskij zhurnal. 2017;2:125-135 (in Russ.). DOI: 10.23648/UMBJ.2017.26.6227. EDN: YTFJCP.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hajam Y.A., Rani R., Ganie S.Y., Sheikh T.A., Javaid D., Qadri S.S., Pramodh S., Alsulimani A., et al. Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. Cells. 2022;11(3):552. DOI: 10.3390/cells11030552.</mixed-citation><mixed-citation xml:lang="en">Hajam Y.A., Rani R., Ganie S.Y., Sheikh T.A., Javaid D., Qadri S.S., Pramodh S., Alsulimani A., et al. Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. Cells. 2022;11(3):552. DOI: 10.3390/cells11030552.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X., Pang Y., Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):190. DOI: 10.1038/s41392-025-02253-4.</mixed-citation><mixed-citation xml:lang="en">Xu X., Pang Y., Fan X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct Target Ther. 2025;10(1):190. DOI: 10.1038/s41392-025-02253-4.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma S., Sharma P., Subedi U., Bhattarai S., Miller C., Manikandan S., Batinic-Haberle I., Spasojevic I., et al. Mn(III) Porphyrin, MnTnBuOE-2-PyP5+, Commonly Known as a Mimic of Superoxide Dismutase Enzyme, Protects Cardiomyocytes from Hypoxia/Reoxygenation Induced Injury via Reducing Oxidative Stress.Int J Mol Sci. 2023;24(7):6159. DOI: 10.3390/ijms24076159.</mixed-citation><mixed-citation xml:lang="en">Sharma S., Sharma P., Subedi U., Bhattarai S., Miller C., Manikandan S., Batinic-Haberle I., Spasojevic I., et al. Mn(III) Porphyrin, MnTnBuOE-2-PyP5+, Commonly Known as a Mimic of Superoxide Dismutase Enzyme, Protects Cardiomyocytes from Hypoxia/Reoxygenation Induced Injury via Reducing Oxidative Stress.Int J Mol Sci. 2023;24(7):6159. DOI: 10.3390/ijms24076159.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
